Can Your Genes Predict How Much Weight You Will Lose on GLP-1 Medications?
Yes. A genome-wide study of 27,885 people taking GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound found that a specific genetic variant in the GLP1R gene is linked to significantly greater weight loss. Variants in two genes also predict whether you are likely to experience nausea and vomiting as side effects.
If you have tried a GLP-1 medication, you may have noticed that your results look very different from someone else on the same drug. Some people lose over 25% of their body weight while others lose less than 5%, or even gain weight. This study found genetic variants that account for part of that difference, though most of it still comes from non-genetic factors. It points toward a future where your DNA could help your doctor choose the right drug and dose for you.
Dr. Kumar’s Take
I find this study genuinely exciting because it is a step toward precision medicine for weight loss drugs. Right now, prescribing GLP-1 medications is largely trial and error. You start a drug, titrate the dose, and hope it works. The fact that a single genetic variant in the GLP1R gene accounts for an extra 0.76 kg of weight loss per copy of the effect allele is meaningful at a population level, and the side effect predictions are even more practical. The combined model sorted people into groups with anywhere from a 5% to a 78% chance of nausea or vomiting, and the GIPR-linked nausea risk showed up only with tirzepatide. Knowing that before starting a drug would change the conversation entirely. The genetic effects are modest, and this is not yet part of everyday practice, but it is the kind of data precision prescribing will need.
What the Researchers Found
This genetic study of GLP-1 medication response was conducted with 23andMe research participants. The group was mostly female (82.4%) with a median age of 52. Before starting treatment, the median BMI was 35.1 kg/m2. After a median of about 8 months on medication, participants reported losing a median of 11.7% of their starting weight. This was self-reported. In electronic health records, the median drop in BMI was smaller, about 5.8%.
The key genetic finding was a missense variant in the GLP1R gene, the gene that encodes the receptor these drugs target. Each copy of this variant was associated with an additional 0.76 kg of weight loss, reaching genome-wide significance (P = 2.9 x 10-10). In simple terms, people who carry this variant tend to respond better to the medication.
The researchers also found genetic variants linked to side effects. Variants in both the GLP1R and GIPR genes predicted the risk of nausea and vomiting. Notably, the GIPR-linked nausea risk only applied to people taking tirzepatide (Mounjaro, Zepbound), not semaglutide (Ozempic, Wegovy). This makes biological sense because tirzepatide targets both the GLP-1 and GIP receptors, while semaglutide only targets GLP-1.
Why Different People Get Different Results
Beyond genetics, several non-genetic factors also predicted how well GLP-1 medications worked. Women lost more weight than men (12.2% versus 10.0% BMI reduction). Tirzepatide users lost more than semaglutide users (4.75 versus 3.71 BMI units), even with similar treatment times. Higher starting BMI and younger age also predicted slightly better results. People with type 2 diabetes lost about 2.87 percentage points less BMI than those without diabetes.
When the researchers combined genetic, demographic, and clinical factors into a single predictive model, they could separate patients into groups expecting anywhere from 6% to 20% weight loss and anywhere from 5% to 78% risk of nausea and vomiting. This kind of stratification could eventually help doctors match patients to the drug most likely to work for them with the fewest side effects.
A Step Toward Personalized Prescribing
A model built on non-genetic factors alone (age, sex, starting BMI, drug, dose and time on treatment) explained about 21.4% of the variation in weight loss. The full model, which added medical diagnoses such as type 2 diabetes and the genetic findings, explained about 25%, with most of that still coming from non-genetic factors. The researchers then tested the model on electronic health records that were not used to build it, and people predicted to lose more weight did lose more.
This matters because roughly one in eight Americans has now used a GLP-1 medication. With drugs this widely prescribed, even modest improvements in matching patients to the right treatment could affect millions of people.
Practical Takeaways
- If you are considering a GLP-1 medication and have access to genetic testing through services like 23andMe, your results may eventually include information relevant to drug response, though clinical guidelines have not yet incorporated these findings.
- The GLP1R variant was linked to nausea on both semaglutide and tirzepatide, while the GIPR-linked nausea risk showed up only in people taking tirzepatide (Mounjaro or Zepbound).
- Talk to your doctor about all the factors that predict your response, including sex, age, starting weight, and diabetes status, so they can set realistic expectations for your treatment.
- Do not stop or switch medications based on genetics alone. These findings are promising but not yet part of standard clinical practice.
Related Studies and Research
- Stopping GLP-1 Drugs Wears Away Their Heart Protection Over Time examines the cardiovascular risks of discontinuing GLP-1 medications.
- Association Between GLP-1 Receptor Agonists and Worsening Mental Illness looks at the mental health side effect profile of these drugs.
- Eating the Same Meals Every Day Helps You Lose More Weight, Study Finds covers behavioral strategies that support weight loss alongside medical treatment.
FAQs
Will a genetic test tell me which GLP-1 drug to take?
Not yet in a clinical setting. While this study identified specific genetic variants that predict both weight loss and side effects, these findings have not been incorporated into prescribing guidelines. However, the research lays the groundwork for pharmacogenetic testing that could eventually guide drug selection. If you already have genetic data from a service like 23andMe, future updates to their health reports may include GLP-1 response information as the science matures.
Why does tirzepatide cause more nausea in some people than semaglutide?
Tirzepatide works on two receptors, the GLP-1 receptor and the GIP receptor, while semaglutide only targets the GLP-1 receptor. This study found that a genetic variant in the GIPR gene increases nausea risk specifically in tirzepatide users. Variation in the GLP1R gene was linked to nausea or vomiting on both drugs.
How much weight can I realistically expect to lose on these medications?
In this study, participants reported a median weight loss of 11.7% of starting body weight after about 8 months of treatment. Health records from a separate group showed a smaller median drop in BMI, about 5.8%. But results vary widely. In an earlier semaglutide study, about 1 in 20 people lost over 25% of their weight, while about 1 in 3 lost less than 5% or gained weight. The predictive model in this study showed that expected weight loss could range from 6% to 20% depending on your combination of genetics, sex, age, starting weight, diabetes status, and which drug you take. Women, younger patients, those with higher starting BMI, and tirzepatide users tended to lose more.
Bottom Line
Your genes play a real role in how well GLP-1 weight loss drugs work for you and whether you will experience nausea as a side effect. This study of nearly 28,000 people identified specific genetic variants in the GLP1R and GIPR genes that predict both outcomes. While personalized prescribing based on DNA is not standard practice yet, this research is a step toward a future where your doctor can use your genetic profile to choose the right obesity medication for you.
